Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Co… (NCT06993454) | Clinical Trial Compass
RecruitingNot Applicable
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
United States12 participantsStarted 2025-04-25
Plain-language summary
The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).
Who can participate
Age range25 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Male or (pre-menopausal) female, aged 25-55 years
✓. Body mass index (BMI) between 25 and 45 kg/m2
✓. Sedentary (1 day or less per week of structured exercise)
✓. Type 2 diabetes mellitus: HbA1c ≥7.5%
✓. Liver fat ≥5.6% based on MRI
✓. Weight stable (± 2 kg) for prior 3 months
Exclusion criteria
✕. Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and/or thiazolidinediones
✕. Any change in glucose-lowering medications within the previous three months.
✕. Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7.
✕. Resting blood pressure ≥ 160/100 mm Hg
✕. Triglycerides ≥ 500 mg/dL
✕. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol
What they're measuring
1
Measurement of Endogenous Glucose Production (EGP)
Timeframe: Day 14
Trial details
NCT IDNCT06993454
SponsorAdventHealth Translational Research Institute